Actinogen Medical Limited
Actinogen Medical Limited
Your view on ACW.AX
Overview
What the company does, where it operates, and who runs it.
About Actinogen Medical Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven G. Gourlay
- Headquarters
- 109 Pitt Street, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven G. Gourlay
- Headquarters
- 109 Pitt Street, Sydney, NSW, AU
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials.
This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome.
Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Actinogen Medical Limited. Starting points for Actinogen Medical Limited: beta 0.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Actinogen Medical Limited. Actinogen Medical Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Actinogen Medical Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.00 | −AUD 0.01 |
| Lowest estimate | −AUD 0.00 | −AUD 0.01 |
| Highest estimate | −AUD 0.00 | −AUD 0.01 |
| Number of analysts | 1 | 1 |
| A year ago | −AUD 0.00 | — |
| Growth vs a year ago | +93.5% | — |
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 38.50M | AUD 0.00 |
| Lowest estimate | AUD 38.50M | AUD 0.00 |
| Highest estimate | AUD 38.50M | AUD 0.00 |
| Number of analysts | 1 | 0 |
| A year ago | AUD 0.00 | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Actinogen Medical Limited. Actinogen Medical Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| IXC.AXInvex Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| NEU.AXNeuren Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | Biotechnology | — | ||
| NYR.AXNyrada Inc. | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $2.2M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.4M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $46.7M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $210,578 | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||
| PRAXPraxis Precision Medicines, Inc. | Healthcare | NASDAQ | $8.4B | ||
| PREDQPredictive Discovery Limited | Healthcare | OTC | $2,996 | ||
| PREV.CNPreveCeutical Medical Inc. | Healthcare | CNQ | $11.7M | ||
| PRLDPrelude Therapeutics Incorporated | Healthcare | NASDAQ | $187.0M | ||
| PRMEPrime Medicine, Inc. | Healthcare | NASDAQ | $645.8M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Actinogen Medical Limited. Coverage tracks Actinogen Medical Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Actinogen Medical Limited.